Lavipharm S.A. (ATH:LAVI)

Market Cap	251.73M +83.1%
Revenue (ttm)	70.32M +28.6%
Net Income	5.74M +48.6%
EPS	0.03 +43.3%
Shares Out	170.78M
PE Ratio	44.88
Forward PE	n/a
Dividend	0.02 (1.36%)
Ex-Dividend Date	Jul 20, 2026

Volume	9,671
Open	1.472
Previous Close	1.500
Day's Range	1.472 - 1.498
52-Week Range	0.781 - 1.738
Beta	1.30
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 306
• Stock Exchange: Athens Stock Exchange
• Ticker Symbol: LAVI

Financial Performance

In 2025, Lavipharm's revenue was 62.58 million, an increase of 18.20% compared to the previous year's 52.95 million. Earnings were 5.99 million, a decrease of -33.36%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error